All blogs
    AI Visibility

    How does AI visibility work for pharma and life sciences brands?

    81% of physicians now use AI professionally, up from 38% in 2023, and 42% of patients bring AI-sourced information into appointments. What that means for a pharma brand's AI visibility.

    A doctor in a white coat holding a stethoscope

    This article covers PR and AI-visibility strategy only. It contains no medical, legal or regulatory advice, and nothing here should be read as such. A pharmaceutical or life sciences company's own medical, legal and regulatory affairs teams should review any specific claim before it goes public.

    Physicians have crossed a threshold with AI faster than almost any other professional group, and their patients are following close behind. The practical result for a pharma or life sciences company is that the same handful of sources an AI system pulls from when a doctor or a patient asks about a drug class, a trial result or a treatment pathway now function as a second audience that matters almost as much as the physician herself. Here is what the adoption data actually shows, and what it changes about how a pharma brand earns visibility.

    81%of physicians use or are aware of AI tools in their practice in 2026
    38%the same share recorded in 2023, before AI use more than doubled
    76%say AI gives them an advantage in caring for patients, up from 65% in 2023

    Source: American Medical Association's 2026 Physician AI Sentiment Report, surveying 1,692 physicians January 15 to February 2, 2026, linked in the article.

    How many physicians are actually using AI now?

    Four in five, according to the organization best positioned to track it. The American Medical Association's 2026 Physician AI Sentiment Report, based on a survey of 1,692 physicians fielded January 15 to February 2, 2026, found that 81% now use or are aware of AI tools in their practice, more than double the 38% recorded in 2023. The share who say AI gives them an advantage in caring for patients rose to 76%, up from 65% three years earlier, and uncertainty about which tools are even available fell to 9%, down from 18% in 2024.

    That adoption curve matters for a specific reason: it is no longer a niche behavior confined to early adopters. A physician reaching for an AI assistant mid-consultation, or before writing up a treatment plan, is now closer to the median behavior than the exception, which means whatever that assistant surfaces about a drug or a therapeutic category is reaching the mainstream of clinical decision-making, not a fringe of it.

    Are patients doing the same thing before they even see a doctor?

    Yes, and it is already changing what happens in the exam room. Wolters Kluwer's 2026 Future Ready Healthcare Survey, conducted by Ipsos among 355 clinicians and 254 patients in mid-March 2026, found that 42% of patients say they frequently or very frequently bring AI-generated information into their appointments, and 59% of clinicians say they welcome or actively engage with that material rather than dismiss it. The same survey found 52% of patients now use AI specifically to research a health condition, and 89% say it is important that AI-generated health answers be checked against a human expert, a sign that trust in the tool is real but conditional.

    Zocdoc's February 2026 AI-Informed Patient Report, based on a Censuswide survey of 1,186 US adults and 1,000 US healthcare providers, adds a sharper detail: 26% of patients have already used AI to ask a health-related question, a share that nearly doubles among adults under 35. Patients feel confident acting on what they're told, 88% say they feel confident about next steps after an AI exchange, but far fewer trust the output outright, just 28% say they trust AI to be accurate without checking it elsewhere.

    A company whose own published information is clear and current gives physicians better material to correct with; a company whose public information is thin leaves the gap to whatever secondary source fills it instead.

    How often does a doctor actually have to correct what a patient brings in?

    Often enough that it has become a routine part of the visit. The same Zocdoc survey found that 83% of doctors say they have had to correct information a patient brought in after an AI exchange. That single figure is the clearest signal that AI-sourced health information is not a background trend, it is now showing up inside the clinical encounter itself, carried in by the patient rather than looked up by the physician.

    For a pharma or life sciences company, that correction moment is a visibility opportunity hiding inside a problem. If an AI system is confidently telling a patient something inaccurate about a drug class, a side-effect profile, or how a treatment compares to an alternative, the physician ends up as the de facto fact-checker, working from whatever accurate public information exists to counter it. A company whose own published, citable information is clear, current and consistent across its site, trial registries and earned coverage gives physicians better material to correct with. A company whose public information is thin or outdated leaves the AI system drawing from whatever secondary source fills the gap instead, with no guarantee it gets the facts right.

    Why does this matter more for pharma than for most other industries?

    Because the cost of a wrong answer is categorically different. AI visibility for healthtech brands already covers how unreliable general-purpose chatbots are on health questions: peer-reviewed testing has found hallucination rates on clinical vignettes running from 50% to 82% across major models. Pharma sits downstream of that same reliability problem, but with an added layer, regulators, physicians and patients all hold a drug claim to a standard that a software company's claim never faces. A healthtech startup that gets miscited can issue a correction. A pharma company whose AI-surfaced information about dosing, interactions or trial outcomes is wrong is dealing with a problem regulatory affairs has to be involved in from the first conversation, not PR alone.

    That is also why the earned-media principle that drives how AI visibility works for B2B brands generally applies here with an extra constraint. AI systems weight third-party, independently verified sources heavily, which for pharma specifically means peer-reviewed publication, regulatory filings, and coverage in trade press that covers clinical and regulatory detail accurately, STAT News, Endpoints News, Fierce Pharma, and similar outlets. A press release announcing trial results carries far less weight with these systems than the same results appearing in a peer-reviewed journal and then being covered by a reporter who read the full paper.

    What can a pharma communications team actually do about this?

    Three things, none of which require guessing at a chatbot's training data. First, keep the public, citable record complete: trial registry entries, peer-reviewed publications, and regulatory filings are the primary sources AI systems and physicians both lean on, and gaps in that record get filled by whatever secondary source is available instead, with no guarantee of accuracy. Second, prioritize earned coverage in outlets that cover the clinical and regulatory substance in detail over broad consumer press that covers the announcement without the substance; the difference between a press release and a blog post is really a difference in who is doing the independent verification, and that verification is exactly what an AI system is weighting. Third, treat the patient-facing side of the public record (condition pages, patient resources, FAQ content) as part of the same visibility surface as scientific communication, since Zocdoc's data shows patients are researching conditions and treatments through AI well before they ever reach a prescriber, and a company's own newsroom page is often the cleanest, most current source available to fill that gap.

    None of this replaces regulatory and medical review. It is the communications layer that determines whether accurate, approved information is actually what AI systems and the physicians who increasingly rely on them find first.

    The direct answer, for anyone who read this far

    Physician use of AI has more than doubled since 2023, reaching 81% in 2026, and patients are close behind: 42% now bring AI-sourced information into appointments, and doctors report having to correct that information 83% of the time. For a pharma or life sciences company, that means the public, citable record, trial registries, peer-reviewed publication, and earned coverage in outlets that cover the clinical detail accurately, is no longer just a communications nice-to-have. It is the raw material physicians and patients are both increasingly drawing from before a prescribing decision is even made. Building a PR strategy around that reality starts with making sure the record is complete and accurate, not with chasing a chatbot.

    If you want help building the earned-media and visibility record for a pharma or life sciences brand, request a quotation and we'll look at what's missing from yours.

    Written by Womedia Team

    White Ocean Media. Related service: AI Visibility